Thank you to our Speakers, Sponsors & Delegates for joining us!
Advancing Personalized Cancer Vaccines with Novel Antigen Selectivity, Optimal Combination Strategies & On-Demand Manufacturing Towards Positive Clinical Readouts & First Approvals
Welcome to the Personalized Cancer Vaccine Summit!
Achieving Affordable Individualized Vaccines for Cancer Patients Faster
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returned to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA, DNA, peptides, viral, dendritic cell and more to share how they are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy.
Companies from the likes of BioNTech, CureVac, Imvax, NousCom and more attending alongside 80+ key stakeholders at the ultimate learning and networking forum to help you and your teams advance your patient-centric pipelines towards the clinic and regulatory approval.
DOWNLOAD THE 2024 BROCHURE
We are live in Boston for the Conference Day Two
Register here or walk in to register on site
Our Expert Personalized Cancer Vaccine Speakers Included:
“In a rapidly evolving scientific area such as cancer vaccines and especially personalized cancer vaccines, scientific exchange is key to spark ideas and new opportunities for collaboration”
Myriam Mendila, Chief Scientific Officer & Head of Research & Development, CureVac
Our 2024 Partners:
“This is the go-to conference in personalized medicine and personalized cancer vaccines. Our new era of personalized drugs, designed and manufactured per patient, has started to show exciting clinical results”
William Jia, Co-founder & Chief Scientific Officer, Virogin Biotech
